

Moderator:

Anil Goyal, PhD, OpenDoors Group

Dr. Goyal is founder and managing director of consulting firm OpenDoors Group. During the last 20 years, he's been part of the leadership teams at 3 public and 3 private biotechnology companies that were primarily oncology focused. He is currently fractional VP of Business Development at MimiVax, LLC, (an immuno-oncology company with Phase II program for glioblastoma) and Esanex Inc., (with an oral Hsp90 inhibitor entering Phase II for lung cancer). Prior to these companies, he served as VP of Business Development at Heat Biologics (HTBX) immuno-oncology company. From 2010-13 he served as CEO and co-founder of Qualiber, Inc., a cancer nanomedicine company launched from UNC-CH. Other companies during his career included: Ascletris Pharmaceuticals (Hangzhou), Optherion, Serenex (Acquired by Pfizer), Millennium Pharma (Acq. by Takeda), Osient Pharma, and Merck & Co.

Dr. Goyal received his Ph.D. in Microbiology and Molecular Genetics jointly from Rutgers, The State University and University of Medicine and Dentistry of New Jersey, and is a Certified Licensing Professional (CLP™) by the Licensing Executives Society, Inc.

Panelists:

Scott Weiner, MBA, Partner, Pappas Ventures

Prior to joining Pappas Ventures in 2006, Scott was an investment manager and research analyst for Silverback Asset Management's life science fund, where he focused on healthcare securities investing. Before joining Silverback, he spent three years at Chicago Growth Partners (formerly William Blair Capital Partners) as a Vice President focusing on healthcare venture capital investments. Previously, he spent three and a half years in investment banking at Lehman Brothers. There, he worked in the healthcare group in New York covering biotechnology, medical devices and drug delivery; the financial sponsors/leveraged finance group in London; and the media/telecom group in Hong Kong.

Scott currently serves as a director for Gentis, Milestone Pharmaceuticals and Rotation Medical; and as an observer for Envisia Therapeutics, IlluminOss Medical, Liquidia Technologies and Thrasos Therapeutics. He previously served as a board observer for LipoScience (NASDAQ: LPDX), and TESARO (NASDAQ: TSRO). Scott has a BS in Biological Anthropology and Anatomy and an MBA from Duke University.



Anita Watkins, JD, Director, REX Strategic Innovations

Anita joined REX in 2012 to help launch REX Strategic Innovations. She is a member of the REX Health Ventures team and oversees REX Health Solutions working to partner with health care innovators to pilot emerging healthcare solutions within the hospital. Prior to joining REX, she served as the Vice President for Government Relations for UNC General Administration.

She received her Juris Doctorate and Master of Regional Planning from the University of North Carolina at Chapel Hill and undergraduate degrees in Political Science and Spanish from North Carolina State University.



Jonathan Meltzer, MBA, Senior Vice President, LabCorp Ventures

Jon Meltzer is a Senior Vice President at LabCorp responsible for the Specialty Oncology Businesses, LabCorp Ventures and select R&D initiatives. Jon joined LabCorp in 2006 has held multiple and often overlapping roles including: Executive Lead for Covance Food Solutions, SVP of Corporate Strategy, President of Enlighten Health, VP/GM of Litholink & next gen sequencing and VP of Corporate Development. Before joining LabCorp, Jon held positions with Pappas Ventures, the Duke Office of Licensing and Ventures, the North Carolina Department of the State Treasurer, the National Research Council of Canada Institute for Biodiagnostics and co-founded a company that manufactured molecular reagents for biomedical research.

Jon received his MBA from the Duke University Fuqua School of business in 2006 and his Ph.D. from the University of Manitoba in 2000.